Derma Sciences Enrolls First Patient in DSC127 Phas...(payers for the management of diabetic ul...),Health

Not merely a problem in the United States, the World Health Organization has recognized that there is a "global epidemic of obesity", with a sharp rise in the incidence of diabetes around the world as part of that epidemic. The International Diabetes Federation has stated that in 2006 there were 246 million people living with diabetes, and that this number is expected to increase to 380 million within 20 years.

Speaking about the first patient entered into this Phase II study, CEO Ed Quilty stated, "I am excited to say that, based on the exceptional results of multiple pre-clinical studies, some of the top wound care researchers in the US have signed on as investigators for this trial. Diabetic foot ulcerations are a major problem in the US and worldwide, as the incidence of diabetes continues to grow rapidly. A significant portion of diabetic ulcerations leads to lower limb amputation, which itself is associated with a high long-term mortality rate." Quilty continued, "Our recent launch of MedEfficiency's EZ-Cast and the investment we are making into DSC127 for diabetic ulcers speaks volumes to our commitment to help reduce the number of these amputations. We are confident that taking a leadership position in this area will help us reach our goal as a leader in advanced wound care, which in turn will drive shareholder value. A drug that is as effective in humans as DSC127 has been shown to be in validated animal models could have blockbuster potential."

DSC127, a topically applied pharmaceutical, has been shown to promote healing in a variety of ways; by increasing keratinocyte proliferation, extracellular matrix production, and vascularization.

Peer reviewed articles on the technology as applied to wound healing and scar reduction have appeared in such journals as the Journal of Peptide Research, Wound Repair and Regeneration, Experimental Der
'/>"/>